文献速递瘢痕与激光

病灶内曲安奈德治疗瘢痕疙瘩与增生性瘢痕的安全性和有效性:系统综述与Meta分析

The safety and efficacy of intralesional triamcinolone acetonide for keloids and hypertrophic scars: A systematic review and meta-analysis.
PubMed 文献 · Burns · 2021-02-24

该系统综述与Meta分析纳入15项随机对照试验,评估病灶内注射曲安奈德(TAC)治疗增生性瘢痕和瘢痕疙瘩的疗效与安全性。短期TAC在血管分布和柔韧性上优于维拉帕米;中长期5-FU、TAC+5-FU及维拉帕米可能效果更优。TAC浓度20 mg/ml或40 mg/ml较5-FU或维拉帕米更易致皮肤萎缩,较5-FU、TAC+5-FU或博来霉素更易致毛细血管扩张。

要点

  • 短期TAC改善血管分布和柔韧性优于维拉帕米。
  • 中长期5-FU、TAC+5-FU或维拉帕米可能优于单用TAC。
  • TAC 20或40 mg/ml较5-FU/维拉帕米更易致皮肤萎缩。

核心结论

  • TAC可能有益于增生性瘢痕和瘢痕疙瘩的短期治疗。
  • 中长期治疗中5-FU、5-FU+TAC和维拉帕米可能产生更优结果。
  • TAC浓度20 mg/ml或40 mg/ml较5-FU或维拉帕米更易致皮肤萎缩,较5-FU、5-FU+TAC或博来霉素更易致毛细血管扩张。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、EMBASE、Cochrane图书馆和ClinicalTrials.gov截至2020年3月25日。
  • 纳入15项英文随机对照试验,比较TAC与安慰剂或其他常用病灶内注射药物。

主要发现

  • 短期TAC相比维拉帕米显著改善血管分布(MD: -0.22, 95% CI: -0.42 to -0.02)和柔韧性(MD: -0.25, 95% CI: -0.44 to -0.06)。
  • 中期5-FU相比TAC显著改善瘢痕高度(SMD: 0.95, 95% CI: 0.15-1.75),而TAC相比5-FU显著改善血管分布(MD: -0.45, 95% CI: -0.76 to -0.14)。
  • 中期TAC+5-FU相比TAC显著改善柔韧性(SMD: 0.98, 95% CI: 0.17-1.78)和色素沉着(MD: 0.45, 95% CI: 0.12-0.78)。
  • 中期A型肉毒毒素相比TAC显著改善柔韧性(SMD: 1.99, 95% CI: 0.98-3.00)。
  • 长期5-FU相比TAC显著改善瘢痕高度(MD: 0.55, 95% CI: 0.17-0.93)但血管分布显著较差(MD: -0.35, 95% CI: -0.65 to -0.05);长期TAC+5-FU相比TAC显著改善瘢痕高度(MD: 1.50, 95% CI: 1.12-1.88)、柔韧性(MD: 0.45, 95% CI: 0.10-0.80)和色素沉着(MD: 0.55, 95% CI: 0.24-0.86)。

关键数值与推荐

  • 主要结局包括瘢痕高度、血管分布、柔韧性、色素沉着、VSS或POSAS总分、毛细血管扩张和皮肤萎缩。
  • 次要结局包括瘢痕整体改善。

临床怎么用

  • 短期治疗增生性瘢痕和瘢痕疙瘩可考虑病灶内注射TAC。
  • 中长期治疗可考虑5-FU、TAC+5-FU或维拉帕米以获得更优效果。
  • 使用TAC浓度20 mg/ml或40 mg/ml时需警惕皮肤萎缩和毛细血管扩张风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Triamcinolone acetonide (TAC) is widely used for hypertrophic scars and keloids; however, TAC has variable efficacy and safety in different individuals. PURPOSE: To evaluate the efficacy and safety of intralesional TAC for treatment of hypertrophic scars and keloids. DATA SOURCES: Searches of PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov prior to 25 March 2020. STUDY SELECTION: Randomized controlled trials in English that compared TAC with a placebo or other medications that are commonly used for intralesional injection in hypertrophic scars and keloids. DATA EXTRACTION: Primary outcomes were reduction in scar height, vascularity, pliability, pigmentation, total scores on the Vancouver Scar Scale (VSS) or patient and observer scar assessment scale (POSAS), telangiectasia, and skin atrophy. Secondary outcomes included overall scar improvement. DATA SYNTHESIS: Fifteen trials met the inclusion criteria. In the short term, TAC was associated with a significant improvement in vascularity (MD: -0.22, 95% CI: -0.42 to -0.02) and pliability (MD: -0.25, 95% CI: -0.44 to -0.06) compared to verapamil. In the medium term, compared to TAC, 5-FU showed a significant improvement in scar height (SMD: 0.95, 95% CI: 0.15-1.75), while TAC led to a significant improvement in vascularity compared to 5-FU (MD: -0.45, 95% CI: -0.76 to -0.14). Compared to TAC, TAC+5-FU showed a significant improvement in pliability (SMD: 0.98, 95% CI: 0.17-1.78) and pigmentation (MD: 0.45, 95% CI: 0.12-0.78). Botulinum toxin type A resulted in significantly better pliability (SMD: 1.99, 95% CI: 0.98-3.00) compared to TAC. In the long term, compared to TAC, 5-FU led to a significant improvement in scar height (MD: 0.55, 95% CI: 0.17-0.93), but significantly less vascularity (MD: -0.35, 95% CI: -0.65 to -0.05). Compared to TAC, TAC+5-FU produced a significant improvement in scar height (MD: 1.50, 95% CI: 1.12-1.88), pliability (MD: 0.45, 95% CI: 0.10-0.80), and pigmentation (MD: 0.55, 95% CI: 0.24-0.86). CONCLUSION: TAC may be beneficial for the short-term treatment of hypertrophic scars and keloids; however, 5-FU, 5-FU+TAC, and verapamil may produce superior results for medium- and long-term treatments. TAC injections at concentrations of 20 mg/ml or 40 mg/ml are more likely to result in skin atrophy compared to 5-FU or verapamil, and are more likely to cause telangiectasia than 5-FU, 5-FU+TAC, or bleomycin.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Zhuang Z, Li Y, Wei X, et al. The safety and efficacy of intralesional triamcinolone acetonide for keloids and hypertrophic scars: A systematic review and meta-analysis. Burns. 2021. PMID: 33814214. doi:10.1016/j.burns.2021.02.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。